JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Plasma IFN-γ may predict pyrotinib efficacy in patients with HER2-positive advanced breast cancer

  • 0Department of Chemoradiotherapy, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China.
Biomedical Reports +

|

June 12, 2025

|

June 12, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Early pyrotinib treatment for HER2-positive advanced breast cancer (ABC) may improve progression-free survival (PFS). Increased plasma IFN-γ levels show prognostic value, while later-line pyrotinib use and higher IL-8 levels are linked to poorer PFS.

Area Of Science

  • Oncology
  • Pharmacology

Background

  • Pyrotinib is used for HER2-positive advanced breast cancer (ABC).
  • Predictive markers for pyrotinib efficacy are limited.
  • Identifying reliable biomarkers is crucial for optimizing treatment.

Purpose Of The Study

  • To explore predictive clinical factors for pyrotinib treatment in HER2-positive ABC.
  • To investigate the prognostic potential of serum cytokines in patients receiving pyrotinib.
  • To identify biomarkers associated with progression-free survival (PFS).

Main Methods

  • Prospective observational study of 58 patients with HER2-positive ABC treated with pyrotinib.
  • Plasma cytokine levels (IL-6, IL-8, IL-10, IL-17, IFN-γ) measured before and after treatment.
  • Analysis of progression-free survival (PFS) in relation to treatment line and cytokine levels.

Main Results

  • Second-line pyrotinib therapy showed improved PFS compared to third- or later-line (17.0 vs. 9.5 months).
  • Increased plasma IL-8 levels correlated with poorer PFS (9.4 vs. 14.0 months).
  • Increased plasma IFN-γ levels correlated with longer PFS (13.0 vs. 11.0 months).
  • Multivariate analysis identified later-line pyrotinib and decreased IFN-γ as independent risk factors for PFS.

Conclusions

  • Early pyrotinib application may enhance PFS in HER2-positive ABC, particularly in trastuzumab-resistant cases.
  • Plasma IFN-γ levels demonstrate potential prognostic value for pyrotinib-treated patients.
  • Further research is needed to confirm the impact on overall survival.

Keywords: